{"title":"稳定性指示UPLC定量定量阿霉素原料药和片剂","authors":"Tandrima Majumder, Shiva Kumar Gubbiyappa, Padmini Iriventi","doi":"10.1186/s43094-025-00802-w","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>In the present study, a new and sensitive UPLC method for stability-indicating study has been established and validated as per the ICH guidelines. To date, no work has been reported on the forced degradation studies of alpelisib using the UPLC technique. Box–Behnken design was used to study the response surface for method optimisation to achieve a good separation with a minimum number of experimental trials. Three independent parameters selected were mobile phase ratio, flow rate of the mobile phase and temperature of the column. Retention time and tailing factor were taken as two responses to obtain mathematical models.</p><h3>Results</h3><p>The chromatography was executed using Waters BEH C<sub>18</sub> UPLC column (2.1 × 50 mm, 1.7micron) at wavelength detection of 246 nm. The optimised assay conditions predicted were isocratic mobile solvent system using 0.1% formic acid buffer solution and acetonitrile in the ratio of 50:50 (V/V), with a flow rate of 0.25 mL per min and injection volume of 4 µL. The method has shown a good response with a total run time of 4 min, retention time was found to be 1.49 min and tailing factor was 0.99 for alpelisib, showing good peak symmetry. The linearity of the method developed is at a range of 10–50 µg/mL with R<sup>2</sup> 0.9955, while the percentage mean recovery for accuracy was of 99.25%. The method developed was precise as % RSD of inter-day and intra-day precision was 0.3 and 0.1, respectively, meeting the specified limits.</p><h3>Conclusion</h3><p>The developed UPLC work is quick and simple with an increased level of linearity, precision, specificity and accuracy as per the ICH criteria and can find application in industries as a regular method for quantification of alpelisib.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00802-w","citationCount":"0","resultStr":"{\"title\":\"Stability-indicating UPLC method for quantification of alpelisib in bulk and tablet formulation by QbD approach\",\"authors\":\"Tandrima Majumder, Shiva Kumar Gubbiyappa, Padmini Iriventi\",\"doi\":\"10.1186/s43094-025-00802-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>In the present study, a new and sensitive UPLC method for stability-indicating study has been established and validated as per the ICH guidelines. To date, no work has been reported on the forced degradation studies of alpelisib using the UPLC technique. Box–Behnken design was used to study the response surface for method optimisation to achieve a good separation with a minimum number of experimental trials. Three independent parameters selected were mobile phase ratio, flow rate of the mobile phase and temperature of the column. Retention time and tailing factor were taken as two responses to obtain mathematical models.</p><h3>Results</h3><p>The chromatography was executed using Waters BEH C<sub>18</sub> UPLC column (2.1 × 50 mm, 1.7micron) at wavelength detection of 246 nm. The optimised assay conditions predicted were isocratic mobile solvent system using 0.1% formic acid buffer solution and acetonitrile in the ratio of 50:50 (V/V), with a flow rate of 0.25 mL per min and injection volume of 4 µL. The method has shown a good response with a total run time of 4 min, retention time was found to be 1.49 min and tailing factor was 0.99 for alpelisib, showing good peak symmetry. The linearity of the method developed is at a range of 10–50 µg/mL with R<sup>2</sup> 0.9955, while the percentage mean recovery for accuracy was of 99.25%. The method developed was precise as % RSD of inter-day and intra-day precision was 0.3 and 0.1, respectively, meeting the specified limits.</p><h3>Conclusion</h3><p>The developed UPLC work is quick and simple with an increased level of linearity, precision, specificity and accuracy as per the ICH criteria and can find application in industries as a regular method for quantification of alpelisib.</p></div>\",\"PeriodicalId\":577,\"journal\":{\"name\":\"Future Journal of Pharmaceutical Sciences\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00802-w\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43094-025-00802-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-025-00802-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Stability-indicating UPLC method for quantification of alpelisib in bulk and tablet formulation by QbD approach
Background
In the present study, a new and sensitive UPLC method for stability-indicating study has been established and validated as per the ICH guidelines. To date, no work has been reported on the forced degradation studies of alpelisib using the UPLC technique. Box–Behnken design was used to study the response surface for method optimisation to achieve a good separation with a minimum number of experimental trials. Three independent parameters selected were mobile phase ratio, flow rate of the mobile phase and temperature of the column. Retention time and tailing factor were taken as two responses to obtain mathematical models.
Results
The chromatography was executed using Waters BEH C18 UPLC column (2.1 × 50 mm, 1.7micron) at wavelength detection of 246 nm. The optimised assay conditions predicted were isocratic mobile solvent system using 0.1% formic acid buffer solution and acetonitrile in the ratio of 50:50 (V/V), with a flow rate of 0.25 mL per min and injection volume of 4 µL. The method has shown a good response with a total run time of 4 min, retention time was found to be 1.49 min and tailing factor was 0.99 for alpelisib, showing good peak symmetry. The linearity of the method developed is at a range of 10–50 µg/mL with R2 0.9955, while the percentage mean recovery for accuracy was of 99.25%. The method developed was precise as % RSD of inter-day and intra-day precision was 0.3 and 0.1, respectively, meeting the specified limits.
Conclusion
The developed UPLC work is quick and simple with an increased level of linearity, precision, specificity and accuracy as per the ICH criteria and can find application in industries as a regular method for quantification of alpelisib.
期刊介绍:
Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.